Search

The metagenome of bacteria colonizing the human intestine is a set of genes that is almost 150 times greater than the set of host genes. Some of these genes encode enzymes whose functioning significantly expands the number of potential pathways for xenobiotic metabolism. The resulting metabolites can exhibit activity different from that of the parent compound. This can decrease the efficacy of pharmacotherapy as well as induce undesirable and potentially life-threatening side effects. Thus, analysis of the biotransformation of small drug-like compounds mediated by the gut microbiota is an important step in the development of new pharmaceutical agents and repurposing of the approved drugs. In vitroresearch, the interaction of drug-like compounds with the gut microbiota is a multistep and time-consuming process. Systematic testing of large sets of chemical structures is associated with a number of challenges, including the lack of standardized techniques and significant financial costs to identify the structure of the final metabolites. Estimation of the compounds’ ability to be biotransformed by the gut microbiota and prediction of the structures of their metabolites are possible in silico. However, the development of computational approaches is limited by the lack of information about chemical structures metabolized by microbiota enzymes. The aim of this study is to create a database containing information on the metabolism of drug-like compounds by the gut microbiota. We created the data set containing information about 368 structures metabolized and 310 structures not metabolized by the human gut microbiota. The HGMMX database is freely available at https://www.way2drug.com/hgmmx. The information presented will be useful in the development of computational approaches for analyzing the impact of the human microbiota on metabolism of drug-like molecules.

A series of new tetrachromophoric systems based on stereoregular tetracyclosiloxanes and dibenzoylmethanatoboron difluoride derivatives have been synthesized and characterized by a complex of physicochemical methods. The photophysical properties of the synthesized compounds are studied by electronic absorption, steady-state, and time-resolved fluorescence spectroscopy. In the synthesized compounds, four dibenzoylmethanatoboron difluoride (DBMBF2)-based fluorophores are in an all-cis arrangement with respect to a cyclotetrasiloxane scaffold. DFT calculations predict that they can form H-type dimers, trimers, or tetramers with an antiparallel orientation of their ground-state dipole moments. Under UV excitation, solutions of these compounds in polar and nonpolar solvents exhibit complex fluorescence consisting of monomer- and excimer-like emissions with different lifetimes. Global fitting analysis reveals the presence of at least four kinetically distinguishable species in the excited state. The studied compounds in solutions have CIE chromaticity coordinates very close to the white color point and are promising objects for the development of next-generation single-emission materials for white illumination.

Many human diseases including cancer, degenerative and autoimmune disorders, diabetes and others are multifactorial. Pharmaceutical agents acting on a single target do not provide their efficient curation. Multitargeted drugs exhibiting pleiotropic pharmacological effects have certain advantages due to the normalization of the complex pathological processes of different etiology. Extracts of medicinal plants (EMP) containing multiple phytocomponents are widely used in traditional medicines for multifactorial disorders’ treatment. Experimental studies of pharmacological potential for multicomponent compositions are quite expensive and time‐consuming. In silico evaluation of EMP the pharmacological potential may provide the basis for selecting the most promising directions of testing and for identifying potential additive/synergistic effects. Multiphytoadaptogen (MPhA) containing 70 major phytocomponents of different chemical classes from 40 medicinal plant extracts has been studied in vitro, in vivo and in clinical researches. Antiproliferative and anti‐tumor activities have been shown against some tumors as well as evidence‐based therapeutic effects against age‐related pathologies. In addition, the neuroprotective, antioxidant, antimutagenic, radioprotective, and immunomodulatory effects of MPhA were confirmed. Analysis of the PASS profiles of the biological activity of MPhA phytocomponents showed that most of the predicted anti‐tumor and anti‐metastatic effects were consistent with the results of laboratory and clinical studies. Antimutagenic, immunomodulatory, radioprotective, neuroprotective and anti‐Parkinsonian effects were also predicted for most of the phytocomponents. Effects associated with positive effects on the male and female reproductive systems have been identified too. Thus, PASS and PharmaExpert can be used to evaluate the pharmacological potential of complex pharmaceutical compositions containing natural products